A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, and Proof of Concept Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Trial Profile

A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, and Proof of Concept Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Discontinued
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs GLWL 01 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Proof of concept
  • Sponsors GLWL Research
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Feb 2017 Status changed from suspended to discontinued because of Insufficient efficacy for this indication.
    • 13 Jan 2017 Status changed from recruiting to suspended Between Study Parts.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top